Each year, The Conference Forum holds a private event for senior level R&D executives from mid to large pharma and biotech companies to address timely and relevant issues impacting R&D decision-making. The 2017 theme was on demonstrating value. The agenda was made up of 20 topic sessions with a speaking faculty of 50 presenters who were mostly from senior R&D leadership with CEOs, investors, representatives from the payer community and government.
We were delighted to have Allergan’s Chief of R&D, Dr David Nicholson as co-chair with Dr Bahija Jallal, EVP, MedImmune and the opening keynote was from Fred Hassan, Managing Director, Healthcare, Warburg Pincus. The 2017 keynotes also included Dr Moncef Slaoui, Chairman of Vaccines, GSK, Joseph Papa, Chairman of the Board, CEO, Valeant Pharmaceuticals and Brent Saunders, MBA, Chairman, President and CEO, Allergen.
We were pleased to welcome for the first time the following executives to the R&D Leadership Summit speaking faculty:
Jeffrey Berkowitz, EVP, Optum
Marc Boutin, JD, CEO, The National Health Council
Robert Califf, MD, Commissioner, FDA
Ron Cohen, MD, President & CEO, Acorda Therapeutics
Steven Frank, Vice-Chairman, Co-Head Global Healthcare, JP Morgan
Zhi Hong, PhD, SVP, Infectious Disease Therapy Area Unit, GSK
Hayato Ishida, General Manager of Project Facilitation and Head of Development Project Management, Mitsubishi Tanabe Pharma Corporation
Monika Lessl, PhD, VP, Head of Corporate Innovation R&D, Bayer AG
Jeremy Levin, Phil, MB BChir, CEO, Ovid Therapeutics
Jan Lundberg, PhD, EVP, Science and Technology and President, Lilly Labs, Eli Lilly & Company
Mathai Mammen, MD, PhD, SVP, Cardiovascular, Metabolic Diseases, Immunology and Oncology, Merck
Steve Miller, MD, MBA, Senior Vice President & Chief Medical Officer, Express Scripts
Diego Miralles, MD, President, Adaptive Therapeutics
Eric Olson, PhD, CSO, Syros Pharmaceuticals
Joseph Papa, Chairman of the Board, CEO, Valeant
Vivek Ramaswamy, Founder and CEO, Roivant Sciences and Axovant Sciences
Alise Reicin, MD, Global Head of Clinical Research, EMD Serono
Roslyn Schneider, MD, Global Patient Affairs Lead, Pfizer Inc
Greg Simon, Director, Biden Cancer Initiative, Former Executive Director, White House Cancer Moonshot Task Force
Kent Thoelke, EVP, Scientific and Medical Affairs, Safety and Commercialization Services, PRA Health Sciences
Akshay Vaishnaw, MD, PhD, EVP R&D, Chief Medical Officer, Alnylam Pharmaceuticals
Rupert Vessey, MA, BM BCh, FRCP, DPhil, President, Research and Early Development, Celgene
Also new to the program for the first time, we welcomed a non-pharma VIP guest keynote from Boeing who was interviewed by our 2016 keynote, Lars Rebien Sorensen, President and CEO, Novo Nordisk.
Many thanks to the executive team at PRA for their support and to Dr Thomas Koestler, Executive Director Health Care, Vatera Health Care Partners for his guidance as well as the entire speaking faculty who brought their vast experience together to share their vision and strategy in:
The format of the conference was a combination of presentations, interviews and panel discussions. The Summit provided plenty of networking opportunities, including breakfast, luncheons, welcome reception, the annual dinner and networking breaks.
The R&D Leadership Summit was open only to senior level R&D executives from clinical stage pharmaceutical, biotech, medical device and vaccine companies.
Our audience was as much a part of the event as our speaking faculty. Our ultimate goal was to foster a Summit environment that inspires positive change to advance R&D and to provide support for the leaders behind the movement. For questions about the R&D Leadership Summit, please contact Valerie@tcfllc.org or Jennifer Moran at Jennifer@tcfllc.org. As the Summit was a private, by invitation only event, seating was limited.
Executive Director, Business Development
*Please note the leadership R&D program for emerging biotechs is open for registration and held in Boston each May and is called the CMO Summit.